BACKGROUND & AIMS:HCV RNA prevalence is a key measure for monitoring progress towards elimination. We estimated the effect of limited and broad availability of direct-acting antiviral (DAA) therapies on HCV RNA prevalence among people with HIV, accounting for variation in testing frequency.
METHODS:Data from six countries contributing to cohorts included in the International Collaboration on Hepatitis Elimination in HIV Cohorts (InCHEHC) were analysed. Follow-up spanned the five years before each country's broad DAA-access date to database closure (5-8 years after broad access). To account for variation in HCV testing frequency, we applied a population-averaged approach to estimate HCV RNA prevalence and quantify changes across the pre-DAA-access (reference), limited-access, and broad-access periods.
RESULTS:Among 107,532 individuals (863,734 person-years), baseline adjusted HCV RNA prevalence ranged from 3.6% (95% CI 3.3-3.9) in the Netherlands to 11.6% (95% CI 10.8-12.4) in Italy. Relative to the pre-DAA period, annual declines in RNA prevalence during limited access ranged from 6% in Italy and Spain (95% CIs 4-7% and 3-8%, respectively) to 21% in the Netherlands (95% CI 17-24%). During broad access, annual declines ranged from 7% in Spain (95% CI 5-9%) to 27% in Switzerland (95% CI 25-30%). From the onset of the COVID-19 pandemic onwards, prevalence declined more slowly in France, Italy, the Netherlands, Spain, and Switzerland, but increased in Australia. After five years of broad DAA access, prevalence ranged from 0.4% (95% CI 0.3-0.5) in the Netherlands to 3.3% (95% CI 2.8-3.8) in Italy.
CONCLUSION:HCV RNA prevalence was stable or decreased slightly before DAA availability across the six InCHEHC countries. Following DAA availability, substantial reductions in HCV RNA prevalence were observed among people with HIV, primarily reflecting the cure of chronic HCV infections and possibly a reduction in transmission risk.
IMPACT AND IMPLICATIONS:Our study shows that the introduction and scale-up of direct-acting antiviral therapies led to substantial and sustained reductions in HCV RNA prevalence among people with HIV across six countries, demonstrating the population-level impact of widespread treatment access on chronic infection and potential transmission. These findings highlight the effectiveness of national direct-acting antiviral strategies, while also underscoring the risk of stalled progress during external disruptions such as the COVID-19 pandemic. We also show that routinely collected clinical data, when appropriately adjusted for testing patterns, can provide reliable estimates of HCV prevalence and help monitor progress toward elimination targets. Sustaining high levels of testing and treatment access, particularly in lower prevalence, post-scale-up settings, will be critical to maintaining momentum toward HCV elimination.